The cutaneous complications of TAK, such as erythema nodosum or pyoderma gangrenosum, are often treated with glucocorticoids (GCs), immunosuppressants, and biologics according to the therapeutic guidelines for TAK.[1] Specifically, these immunosuppressants and biologics include methotrexate, azathioprine, tumor necrotizing factor (TNF) inhibitors, or interleukin-6 (IL-6) receptor inhibitors. The gene discussed is IL6; the disease is Erythema nodosum.